<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33393416</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>01</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1555-8584</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>RNA biology</Title><ISOAbbreviation>RNA Biol</ISOAbbreviation></Journal><ArticleTitle>Adenosine-to-inosine RNA editing in neurological development and disease.</ArticleTitle><Pagination><StartPage>999</StartPage><EndPage>1013</EndPage><MedlinePgn>999-1013</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/15476286.2020.1867797</ELocationID><Abstract><AbstractText>Adenosine-to-inosine (A-to-I) editing is one of the most prevalent post-transcriptional RNA modifications in metazoan. This reaction is catalysed by enzymes called adenosine deaminases acting on RNA (ADARs). RNA editing is involved in the regulation of protein function and gene expression. The numerous A-to-I editing sites have been identified in both coding and non-coding RNA transcripts. These editing sites are also found in various genes expressed in the central nervous system (CNS) and play an important role in neurological development and brain function. Aberrant regulation of RNA editing has been associated with the pathogenesis of neurological and psychiatric disorders, suggesting the physiological significance of RNA editing in the CNS. In this review, we discuss the current knowledge of editing on neurological disease and development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Yuxi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Research Institute for Biomedical Sciences, Tokyo University of Science, Noda-shi, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okada</LastName><ForeName>Shunpei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Research Institute for Biomedical Sciences, Tokyo University of Science, Noda-shi, Chiba, Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sakurai</LastName><ForeName>Masayuki</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6920-1746</Identifier><AffiliationInfo><Affiliation>Research Institute for Biomedical Sciences, Tokyo University of Science, Noda-shi, Chiba, Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>RNA Biol</MedlineTA><NlmUniqueID>101235328</NlmUniqueID><ISSNLinking>1547-6286</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C496946">KCNA1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C524940">MIRN21 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525709">MIRN221 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C525710">MIRN222 microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C573498">MIRN376C microRNA, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D035683">MicroRNAs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D044405">Receptor, Serotonin, 5-HT2C</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018091">Receptors, AMPA</NameOfSubstance></Chemical><Chemical><RegistryNumber>147173-20-4</RegistryNumber><NameOfSubstance UI="D051662">Kv1.1 Potassium Channel</NameOfSubstance></Chemical><Chemical><RegistryNumber>5A614L51CT</RegistryNumber><NameOfSubstance UI="D007288">Inosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>P6W5IXV8V9</RegistryNumber><NameOfSubstance UI="C104722">glutamate receptor ionotropic, AMPA 2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C567924">Infantile Epileptic-Dyskinetic Encephalopathy</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001254" MajorTopicYN="N">Astrocytoma</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001714" MajorTopicYN="N">Bipolar Disorder</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016543" MajorTopicYN="N">Central Nervous System Neoplasms</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004827" MajorTopicYN="N">Epilepsy</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007288" MajorTopicYN="N">Inosine</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051662" MajorTopicYN="N">Kv1.1 Potassium Channel</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D035683" MajorTopicYN="N">MicroRNAs</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017393" MajorTopicYN="Y">RNA Editing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044405" MajorTopicYN="N">Receptor, Serotonin, 5-HT2C</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018091" MajorTopicYN="N">Receptors, AMPA</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012559" MajorTopicYN="N">Schizophrenia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013036" MajorTopicYN="N">Spasms, Infantile</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">5-HT2CR</Keyword><Keyword MajorTopicYN="N">A-to-I RNA editing</Keyword><Keyword MajorTopicYN="N">ADAR</Keyword><Keyword MajorTopicYN="N">AGS</Keyword><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">GluA2</Keyword><Keyword MajorTopicYN="N">Post-transcriptional RNA modification</Keyword><Keyword MajorTopicYN="N">bipolar disorder</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">epilepsy</Keyword><Keyword MajorTopicYN="N">miRNA</Keyword><Keyword MajorTopicYN="N">schizophrenia</Keyword><Keyword MajorTopicYN="N">viral RNA</Keyword></KeywordList><CoiStatement>No potential conflict of interest was reported by the authors.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>4</Day><Hour>8</Hour><Minute>50</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33393416</ArticleId><ArticleId IdType="pmc">PMC8216190</ArticleId><ArticleId IdType="doi">10.1080/15476286.2020.1867797</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Flamand MN, Meyer KD.. The epitranscriptome and synaptic plasticity. Curr Opin Neurobiol. 2019;59:41&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858947</ArticleId><ArticleId IdType="pubmed">31108373</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishikura K. A-to-I editing of coding and non-coding RNAs by ADARs. Nat Rev Mol Cell Biol. 2016;17(2):83&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4824625</ArticleId><ArticleId IdType="pubmed">26648264</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim U, Wang Y, Sanford T, et al. Molecular cloning of cDNA for double-stranded RNA adenosine deaminase, a candidate enzyme for nuclear RNA editing. Proc Natl Acad Sci U S A. 1994;91(24):11457&#x2013;11461</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45250</ArticleId><ArticleId IdType="pubmed">7972084</ArticleId></ArticleIdList></Reference><Reference><Citation>Melcher T, Maas S, Herb A, et al. A mammalian RNA editing enzyme. Nature. 1996;379(6564):460&#x2013;464.</Citation><ArticleIdList><ArticleId IdType="pubmed">8559253</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen CX, Cho&#xa0; DS, Wang Q, et al. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. Rna. 2000;6(5):755&#x2013;767</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1369955</ArticleId><ArticleId IdType="pubmed">10836796</ArticleId></ArticleIdList></Reference><Reference><Citation>Stefl R, Xu M, Skrisovska L, et al. Structure and specific RNA binding of ADAR2 double-stranded RNA binding motifs. Structure. 2006;14(2):345&#x2013;355.</Citation><ArticleIdList><ArticleId IdType="pubmed">16472753</ArticleId></ArticleIdList></Reference><Reference><Citation>Patterson JB, Samuel CE. Expression and regulation by interferon of a double-stranded-RNA-specific adenosine deaminase from human cells: evidence for two forms of the deaminase. Mol Cell Biol. 1995;15(10):5376&#x2013;5388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC230787</ArticleId><ArticleId IdType="pubmed">7565688</ArticleId></ArticleIdList></Reference><Reference><Citation>Pestal K, Funk C, Snyder JM, et al. Isoforms of RNA-editing enzyme ADAR1 independently control nucleic acid sensor MDA5-driven autoimmunity and multi-organ development. Immunity. 2015;43(5):933&#x2013;944</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4654992</ArticleId><ArticleId IdType="pubmed">26588779</ArticleId></ArticleIdList></Reference><Reference><Citation>Walkley CR, Li JB. Rewriting the transcriptome: adenosine-to-inosine RNA editing by ADARs. Genome Biol. 2017;18(1):205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663115</ArticleId><ArticleId IdType="pubmed">29084589</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Chung DH, Monteleone LR, et al. RNA binding candidates for human ADAR3 from substrates of a gain of function mutant expressed in neuronal cells. Nucleic Acids Res. 2019;47(20):10801&#x2013;10814.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6846710</ArticleId><ArticleId IdType="pubmed">31552420</ArticleId></ArticleIdList></Reference><Reference><Citation>Mladenova D, Barry G, Konen LM, et al. Adar3 is involved in learning and memory in Mice. Front Neurosci. 2018;12:243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5914295</ArticleId><ArticleId IdType="pubmed">29719497</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q, Miyakoda M, Yang W, et al. Stress-induced apoptosis associated with null mutation of ADAR1 RNA editing deaminase gene. J Biol Chem. 2004;279(6):4952&#x2013;4961.</Citation><ArticleIdList><ArticleId IdType="pubmed">14613934</ArticleId></ArticleIdList></Reference><Reference><Citation>Higuchi M, Maas S, Single FN, et al. Point mutation in an AMPA receptor gene rescues lethality in mice deficient in the RNA-editing enzyme ADAR2. Nature. 2000;406(6791):78&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">10894545</ArticleId></ArticleIdList></Reference><Reference><Citation>Hood JL, Emeson RB. Editing of neurotransmitter receptor and ion channel RNAs in the nervous system. Curr Top Microbiol Immunol. 2012;353:61&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4109139</ArticleId><ArticleId IdType="pubmed">21796513</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto Y, Cohen HY, Levanon EY. Mammalian conserved ADAR targets comprise only a small fragment of the human editosome. Genome Biol. 2014;15(1):R5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4053846</ArticleId><ArticleId IdType="pubmed">24393560</ArticleId></ArticleIdList></Reference><Reference><Citation>Lev-Maor G, Sorek R, Levanon EY, et al. RNA-editing-mediated exon evolution. Genome Biol. 2007;8(2):R29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852406</ArticleId><ArticleId IdType="pubmed">17326827</ArticleId></ArticleIdList></Reference><Reference><Citation>Rueter SM, Dawson TR, Emeson RB. Regulation of alternative splicing by RNA editing. Nature. 1999;399(6731):75&#x2013;80.</Citation><ArticleIdList><ArticleId IdType="pubmed">10331393</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchert GM, Gilmore BL, Spengler RM, et al. Adenosine deamination in human transcripts generates novel microRNA binding sites. Hum Mol Genet. 2009;18(24):4801&#x2013;4807.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2778373</ArticleId><ArticleId IdType="pubmed">19776031</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakano M, Fukami T, Gotoh S, et al. A-to-I RNA editing up-regulates human dihydrofolate reductase in breast cancer. J Biol Chem. 2017;292(12):4873&#x2013;4884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5377802</ArticleId><ArticleId IdType="pubmed">28188287</ArticleId></ArticleIdList></Reference><Reference><Citation>Stellos K, Gatsiou A, Stamatelopoulos K, et al. Adenosine-to-inosine RNA editing controls cathepsin S expression in atherosclerosis by enabling HuR-mediated post-transcriptional regulation. Nat Med. 2016;22(10):1140&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">27595325</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaswami G, Zhang R, Piskol R, et al. Identifying RNA editing sites using RNA sequencing data alone. Nat Methods. 2013;10(2):128&#x2013;132.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3676881</ArticleId><ArticleId IdType="pubmed">23291724</ArticleId></ArticleIdList></Reference><Reference><Citation>Bazak L, Haviv A, Barak M, et al. A-to-I RNA editing occurs at over a hundred million genomic sites, located in a majority of human genes. Genome Res. 2014;24(3):365&#x2013;376.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941102</ArticleId><ArticleId IdType="pubmed">24347612</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeman Y, Levanon EY, Jantsch MF, et al. RNA editing level in the mouse is determined by the genomic repeat repertoire. RNA. 2006;12(10):1802&#x2013;1809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1581974</ArticleId><ArticleId IdType="pubmed">16940548</ArticleId></ArticleIdList></Reference><Reference><Citation>Danecek P, Nell&#xe5;ker C, McIntyre RE, et al. High levels of RNA-editing site conservation amongst 15 laboratory mouse strains. Genome Biol. 2012;13(4):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3446300</ArticleId><ArticleId IdType="pubmed">22524474</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakurai M, Ueda H, Yano T, et al. A biochemical landscape of A-to-I RNA editing in the human brain transcriptome. Genome Res. 2014;24(3):522&#x2013;534.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3941116</ArticleId><ArticleId IdType="pubmed">24407955</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahn JH, Lee JH, Li G, et al. Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res. 2012;22(1):142&#x2013;150</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3246201</ArticleId><ArticleId IdType="pubmed">21960545</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanov A, Memczak S, Wyler E, et al. Analysis of intron sequences reveals hallmarks of circular RNA biogenesis in animals. Cell Rep. 2015;10(2):170&#x2013;177</Citation><ArticleIdList><ArticleId IdType="pubmed">25558066</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright A, Vissel B. The essential role of AMPA receptor GluR2 subunit RNA editing in the normal and diseased brain. Front Mol Neurosci. 2012;5:34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3324117</ArticleId><ArticleId IdType="pubmed">22514516</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingledine R, Borges K, Bowie D, et al. The glutamate receptor ion channels. Pharmacol Rev. 1999;51(1):7&#x2013;61</Citation><ArticleIdList><ArticleId IdType="pubmed">10049997</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusa R, Zimmermann F, Koh DS, et al. Early-onset epilepsy and postnatal lethality associated with an editing-deficient GluR-B allele in mice. Science. 1995;270(5242):1677&#x2013;1680</Citation><ArticleIdList><ArticleId IdType="pubmed">7502080</ArticleId></ArticleIdList></Reference><Reference><Citation>MAJ van den Bos, Geevasinga N, Higashihara M, et al. Pathophysiology and diagnosis of ALS: insights from advances in neurophysiological techniques. Int J Mol Sci. 2019;20(11):2818</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6600525</ArticleId><ArticleId IdType="pubmed">31185581</ArticleId></ArticleIdList></Reference><Reference><Citation>Takuma H, Kwak S, Yoshizawa T, et al. Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors, selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Ann Neurol. 1999;46(6):806&#x2013;815.</Citation><ArticleIdList><ArticleId IdType="pubmed">10589532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Ito K, Sun H, et al. Glutamate receptors: RNA editing and death of motor neurons. Nature. 2004;427(6977):801.</Citation><ArticleIdList><ArticleId IdType="pubmed">14985749</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Yamashita T, Aizawa H, et al. Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiol Dis. 2012;45(3):1121&#x2013;1128.</Citation><ArticleIdList><ArticleId IdType="pubmed">22226999</ArticleId></ArticleIdList></Reference><Reference><Citation>Hideyama T, Yamashita T, Suzuki T, et al. Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. J Neurosci. 2010;30(36):11917&#x2013;11925.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6633551</ArticleId><ArticleId IdType="pubmed">20826656</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H, Sawada J, Hideyama T, et al. TDP-43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010;120(1):75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20372915</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Hideyama T, Hachiga K, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3(1):1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Aizawa H, Teramoto S, et al. Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons. Sci Rep. 2017;7(1):39994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5206745</ArticleId><ArticleId IdType="pubmed">28045133</ArticleId></ArticleIdList></Reference><Reference><Citation>Akamatsu M, Yamashita T, Hirose N, et al. The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Sci Rep. 2016;6(1):28649.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4923865</ArticleId><ArticleId IdType="pubmed">27350567</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Chai HL, Teramoto S, et al. Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Mol Med. 2013;5(11):1710&#x2013;1719.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3840487</ArticleId><ArticleId IdType="pubmed">24115583</ArticleId></ArticleIdList></Reference><Reference><Citation>Catarzi D, Colotta V, Varano F. Competitive AMPA receptor antagonists. Med Res Rev. 2007;27(2):239&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pubmed">16892196</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldmeyer D, Kask K, Brusa R, et al. Neurological dysfunctions in mice expressing different levels of the Q/R site-unedited AMPAR subunit GluR-B. Nat Neurosci. 1999;2(1):57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">10195181</ArticleId></ArticleIdList></Reference><Reference><Citation>Krestel HE, Shimshek DR, Jensen V, et al. A genetic switch for epilepsy in adult mice. J Neurosci. 2004;24(46):10568&#x2013;10578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6730297</ArticleId><ArticleId IdType="pubmed">15548671</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Z, Agopyan N, Miu P, et al. Enhanced LTP in mice deficient in the AMPA receptor GluR2. Neuron. 1996;17(5):945&#x2013;956</Citation><ArticleIdList><ArticleId IdType="pubmed">8938126</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitaura H, Sonoda M, Teramoto S, et al. Ca(2+) -permeable AMPA receptors associated with epileptogenesis of hypothalamic hamartoma. Epilepsia. 2017;58(4):p. e59-e63.</Citation><ArticleIdList><ArticleId IdType="pubmed">28195308</ArticleId></ArticleIdList></Reference><Reference><Citation>Kortenbruck G, Berger E, Speckmann EJ, et al. RNA editing at the Q/R site for the glutamate receptor subunits GLUR2, GLUR5, and GLUR6 in hippocampus and temporal cortex from epileptic patients. Neurobiol Dis. 2001;8(3):459&#x2013;468</Citation><ArticleIdList><ArticleId IdType="pubmed">11442354</ArticleId></ArticleIdList></Reference><Reference><Citation>Krestel H, Raffel S, von Lehe M, et al. Differences between RNA and DNA due to RNA editing in temporal lobe epilepsy. Neurobiol Dis. 2013;56:66&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">23607937</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan TY, Sedm&#xed;k J, Fitzgerald MP, et al. Bi-allelic ADARB1 variants associated with microcephaly, intellectual disability, and seizures. Am J Hum Genet. 2020;106(4):467&#x2013;483</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118584</ArticleId><ArticleId IdType="pubmed">32220291</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroofian R, Sedm&#xed;k J, Mazaheri N, et al. Biallelic variants in ADARB1, encoding a dsRNA-specific adenosine deaminase, cause a severe developmental and epileptic encephalopathy. J Med Genet. 2020. DOI:10.1136/jmedgenet-2020-107048</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmedgenet-2020-107048</ArticleId><ArticleId IdType="pmc">PMC8327408</ArticleId><ArticleId IdType="pubmed">32719099</ArticleId></ArticleIdList></Reference><Reference><Citation>Salpietro V, Dixon CL, Guo H, et al. AMPA receptor GluA2 subunit defects are a cause of neurodevelopmental disorders. Nat Commun. 2019;10(1):3094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626132</ArticleId><ArticleId IdType="pubmed">31300657</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeano F, Tomaselli S, Locatelli F, et al. A-to-I RNA editing: the &#x201c;ADAR&#x201d; side of human cancer. Semin Cell Dev Biol. 2012;23(3):244&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">21930228</ArticleId></ArticleIdList></Reference><Reference><Citation>Stupp R, van den Bent MJ, Hegi ME. Optimal role of temozolomide in the treatment of malignant gliomas. Curr Neurol Neurosci Rep. 2005;5(3):198&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">15865885</ArticleId></ArticleIdList></Reference><Reference><Citation>Maas S, Patt S, Schrey M, et al. Underediting of glutamate receptor GluR-B mRNA in malignant gliomas. Proc Natl Acad Sci U S A. 2001;98(25):14687&#x2013;14692</Citation><ArticleIdList><ArticleId IdType="pmc">PMC64742</ArticleId><ArticleId IdType="pubmed">11717408</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiuchi S, Tsuzuki K, Yoshida Y, et al. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat Med. 2002;8(9):971&#x2013;978.</Citation><ArticleIdList><ArticleId IdType="pubmed">12172541</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishiuchi S, Yoshida Y, Sugawara K, et al. Ca2+-permeable AMPA receptors regulate growth of human glioblastoma via Akt activation. J Neurosci. 2007;27(30):7987&#x2013;8001</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6672718</ArticleId><ArticleId IdType="pubmed">17652589</ArticleId></ArticleIdList></Reference><Reference><Citation>Giorgetti M, Tecott LH. Contributions of 5-HT(2C) receptors to multiple actions of central serotonin systems. Eur J Pharmacol. 2004;488(1&#x2013;3):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">15044029</ArticleId></ArticleIdList></Reference><Reference><Citation>Burns CM, Chu H, Rueter SM, et al. Regulation of serotonin-2C receptor G-protein coupling by RNA editing. Nature. 1997;387(6630):303&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153397</ArticleId></ArticleIdList></Reference><Reference><Citation>Slotkin W, Nishikura K. Adenosine-to-inosine RNA editing and human disease. Genome Med. 2013;5(11):105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3979043</ArticleId><ArticleId IdType="pubmed">24289319</ArticleId></ArticleIdList></Reference><Reference><Citation>Niswender CM, Copeland SC, Herrick-Davis K, et al. RNA editing of the human serotonin 5-hydroxytryptamine 2C receptor silences constitutive activity. J Biol Chem. 1999;274(14):9472&#x2013;9478.</Citation><ArticleIdList><ArticleId IdType="pubmed">10092629</ArticleId></ArticleIdList></Reference><Reference><Citation>Abbas AI, Urban DJ, Jensen NH, et al. Assessing serotonin receptor mRNA editing frequency by a novel ultra high-throughput sequencing method. Nucleic Acids Res. 2010;38(10):e118.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2879535</ArticleId><ArticleId IdType="pubmed">20185571</ArticleId></ArticleIdList></Reference><Reference><Citation>Price RD, Weiner DM, Chang MS, et al. RNA editing of the human serotonin 5-HT2C receptor alters receptor-mediated activation of G13 protein. J Biol Chem. 2001;276(48):44663&#x2013;44668</Citation><ArticleIdList><ArticleId IdType="pubmed">11572865</ArticleId></ArticleIdList></Reference><Reference><Citation>Marion S, Weiner DM, Caron MG. RNA editing induces variation in desensitization and trafficking of 5-hydroxytryptamine 2c receptor isoforms. J Biol Chem. 2004;279(4):2945&#x2013;2954.</Citation><ArticleIdList><ArticleId IdType="pubmed">14602721</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahlstedt H, Daniel C, Enstero M, et al. Large-scale mRNA sequencing determines global regulation of RNA editing during brain development. Genome Res. 2009;19(6):978&#x2013;986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2694479</ArticleId><ArticleId IdType="pubmed">19420382</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Grimberg A, Teegarden S, et al. Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci. 2008;28(48):12834&#x2013;12844.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2615198</ArticleId><ArticleId IdType="pubmed">19036977</ArticleId></ArticleIdList></Reference><Reference><Citation>Chagraoui A, Thibaut F, Skiba M, et al. 5-HT2C receptors in psychiatric disorders: A review. Prog Neuropsychopharmacol Biol Psychiatry. 2016;66:120&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pubmed">26739950</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenck F, B&#xf6;s M, Wichmann J, et al. The role of 5-HT2C receptors in affective disorders. Expert Opin Investig Drugs. 1998;7(10):1587&#x2013;1599.</Citation><ArticleIdList><ArticleId IdType="pubmed">15991903</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurevich I, Tamir H, Arango V, et al. Altered editing of serotonin 2C receptor pre-mRNA in the prefrontal cortex of depressed suicide victims. Neuron. 2002;34(3):349&#x2013;356.</Citation><ArticleIdList><ArticleId IdType="pubmed">11988167</ArticleId></ArticleIdList></Reference><Reference><Citation>Niswender CM, Herrick-Davis K, Dilley GE, et al. RNA editing of the human serotonin 5-HT2C receptor. alterations in suicide and implications for serotonergic pharmacotherapy. Neuropsychopharmacology. 2001;24(5):478&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pubmed">11282248</ArticleId></ArticleIdList></Reference><Reference><Citation>Dracheva S, Patel N, Woo DA, et al. Increased serotonin 2C receptor mRNA editing: a possible risk factor for suicide. Mol Psychiatry. 2008;13(11):1001&#x2013;1010</Citation><ArticleIdList><ArticleId IdType="pubmed">17848916</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamoto K, Kato T. RNA editing of serotonin 2C receptor in human postmortem brains of major mental disorders. Neurosci Lett. 2003;346(3):169&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">12853111</ArticleId></ArticleIdList></Reference><Reference><Citation>Weissmann D, van der Laan S, Underwood MD, et al. Region-specific alterations of A-to-I RNA editing of serotonin 2c receptor in the cortex of suicides with major depression. Transl Psychiatry. 2016;6(8):e878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5022077</ArticleId><ArticleId IdType="pubmed">27576167</ArticleId></ArticleIdList></Reference><Reference><Citation>Pongs O. Voltage-gated potassium channels: from hyperexcitability to excitement. FEBS Lett. 1999;452(1&#x2013;2):31&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">10376673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kamb A, Iverson LE, Tanouye MA. Molecular characterization of Shaker, a Drosophila gene that encodes a potassium channel. Cell. 1987;50(3):405&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">2440582</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutman GA, Chandy KG, Grissmer S, et al. International union of pharmacology. LIII. Nomenclature and molecular relationships of voltage-gated potassium channels. Pharmacol Rev. 2005;57(4):473&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382104</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhalla T, Rosenthal JJ, Holmgren M, et al. Control of human potassium channel inactivation by editing of a small mRNA hairpin. Nat Struct Mol Biol. 2004;11(10):950&#x2013;956</Citation><ArticleIdList><ArticleId IdType="pubmed">15361858</ArticleId></ArticleIdList></Reference><Reference><Citation>Decher N, Streit AK, Rapedius M, et al. RNA editing modulates the binding of drugs and highly unsaturated fatty acids to the open pore of Kv potassium channels. Embo J. 2010;29(13):2101&#x2013;2113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905254</ArticleId><ArticleId IdType="pubmed">20461057</ArticleId></ArticleIdList></Reference><Reference><Citation>Streit AK, Derst C, Wegner S, et al. RNA editing of Kv1.1 channels may account for reduced ictogenic potential of 4-aminopyridine in chronic epileptic rats. Epilepsia. 2011;52(3):645&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">21371023</ArticleId></ArticleIdList></Reference><Reference><Citation>Graves TD, Cha Y-H, Hahn AF, et al. Episodic ataxia type 1: clinical characterization, quality of life and genotype-phenotype correlation. Brain. 2014;137(Pt 4):1009&#x2013;1018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3959554</ArticleId><ArticleId IdType="pubmed">24578548</ArticleId></ArticleIdList></Reference><Reference><Citation>Imbrici P, D&#x2019;Adamo MC, Kullmann DM, et al. Episodicataxia type 1 mutations in the KCNA1 gene impair the fast inactivation properties of the human potassium channels Kv1.4-1.1/Kv&#x3b2;1.1 and Kv1.4-1.1/Kv&#x3b2;1.2. Eur J Neurosci. 2006;24(11):3073&#x2013;3083.</Citation><ArticleIdList><ArticleId IdType="pubmed">17156368</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomlinson SE, Rajakulendran S, Tan SV, et al. Clinical, genetic, neurophysiological and functional study of new mutations in episodic ataxia type 1. J Neurol Neurosurg Psychiatry. 2013;84(10):1107&#x2013;1112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4332158</ArticleId><ArticleId IdType="pubmed">23349320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrick-Kiddie EA, Rosenthal JJC, Ayers GD, et al. Mutations underlying Episodic Ataxia type-1 antagonize Kv1.1 RNA editing. Sci Rep. 2017;7(1):41095.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316942</ArticleId><ArticleId IdType="pubmed">28216637</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B, Hur S. How RIG-I like receptors activate MAVS. Curr Opin Virol. 2015;12:91&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4470786</ArticleId><ArticleId IdType="pubmed">25942693</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddicoat BJ, Piskol R, Chalk AM, et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself. Science. 2015;349(6252):1115&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444807</ArticleId><ArticleId IdType="pubmed">26275108</ArticleId></ArticleIdList></Reference><Reference><Citation>Mannion NM, Greenwood SM, Young R, et al. The RNA-editing enzyme ADAR1 controls innate immune responses to RNA. Cell Rep. 2014;9(4):1482&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4542304</ArticleId><ArticleId IdType="pubmed">25456137</ArticleId></ArticleIdList></Reference><Reference><Citation>Orcesi S, La Piana R, Fazzi E. Aicardi-Goutieres syndrome. Br Med Bull. 2009;89:183&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">19129251</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow YJ, Manel N. Aicardi-Goutieres syndrome and the type I interferonopathies. Nat Rev Immunol. 2015;15(7):429&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">26052098</ArticleId></ArticleIdList></Reference><Reference><Citation>Rice GI, Forte GMA, Mannion NM, et al. Mutations in ADAR1 cause Aicardi-Gouti&#xe8;res syndrome associated with a type I interferon signature. Nat Genet. 2012;44(11):1243&#x2013;1248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154508</ArticleId><ArticleId IdType="pubmed">23001123</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmelzer L, Smitka M, Wolf C, et al. Variable clinical phenotype in two siblings with Aicardi-Gouti&#xe8;res syndrome type 6 and a novel mutation in the ADAR gene. Eur J Paediatr Neurol. 2018;22(1):186&#x2013;189.</Citation><ArticleIdList><ArticleId IdType="pubmed">29221912</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmad S, Mu X, Yang F, et al. Breaching self-tolerance to Alu Duplex RNA underlies MDA5-mediated inflammation. Cell. 2018;172(4):797&#x2013;810. e13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807104</ArticleId><ArticleId IdType="pubmed">29395326</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono M, Akiyama M. Dyschromatosis symmetrica hereditaria and reticulate acropigmentation of Kitamura: an update. J Dermatol Sci. 2019;93(2):75&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">30692041</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondo T, Suzuki T, Ito S, et al. Dyschromatosis symmetrica hereditaria associated with neurological disorders. J Dermatol. 2008;35(10):662&#x2013;666</Citation><ArticleIdList><ArticleId IdType="pubmed">19017046</ArticleId></ArticleIdList></Reference><Reference><Citation>Suzuki N, Suzuki T, Inagaki K, et al. Ten novel mutations of the ADAR1 gene in Japanese patients with dyschromatosis symmetrica hereditaria. J Invest Dermatol. 2007;127(2):309&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917490</ArticleId></ArticleIdList></Reference><Reference><Citation>Livingston JH, Lin JP, Dale RC, et al. A type I interferon signature identifies bilateral striatal necrosis due to mutations in ADAR1. J Med Genet. 2014;51(2):76&#x2013;82</Citation><ArticleIdList><ArticleId IdType="pubmed">24262145</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow YJ, Zaki M, Abdel-Hamid M, et al. Mutations in ADAR1, IFIH1, and RNASEH2B presenting as spastic paraplegia. Neuropediatrics. 2014;45(6):386&#x2013;393.</Citation><ArticleIdList><ArticleId IdType="pubmed">25243380</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel CE. ADARs: viruses and innate immunity. Curr Top Microbiol Immunol. 2012;353:163&#x2013;195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3867276</ArticleId><ArticleId IdType="pubmed">21809195</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;linas JF, Clerzius G, Shaw E, et al. Enhancement of replication of RNA viruses by ADAR1 via RNA editing and inhibition of RNA-activated protein kinase. J Virol. 2011;85(17):8460&#x2013;8466</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3165853</ArticleId><ArticleId IdType="pubmed">21490091</ArticleId></ArticleIdList></Reference><Reference><Citation>Moss WJ, Griffin DE. Global measles elimination. Nat Rev Microbiol. 2006;4(12):900&#x2013;908.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7097605</ArticleId><ArticleId IdType="pubmed">17088933</ArticleId></ArticleIdList></Reference><Reference><Citation>Oldstone MB. Modeling subacute sclerosing panencephalitis in a transgenic mouse system: uncoding pathogenesis of disease and illuminating components of immune control. Curr Top Microbiol Immunol. 2009;330:31&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">19203103</ArticleId></ArticleIdList></Reference><Reference><Citation>Bass BL, Weintraub H, Cattaneo R, et al. Biased hypermutation of viral RNA genomes could be due to unwinding/modification of double-stranded RNA. Cell. 1989;56(3):331.</Citation><ArticleIdList><ArticleId IdType="pubmed">2914324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ward SV, George CX, Welch MJ, et al. RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis. Proc Natl Acad Sci U S A. 2011;108(1):331&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3017198</ArticleId><ArticleId IdType="pubmed">21173229</ArticleId></ArticleIdList></Reference><Reference><Citation>Toth AM, Li Z, Cattaneo R, et al. RNA-specific adenosine deaminase ADAR1 suppresses measles virus-induced apoptosis and activation of protein kinase PKR. J Biol Chem. 2009;284(43):29350&#x2013;29356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2785566</ArticleId><ArticleId IdType="pubmed">19710021</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaller CK, Mastorakos GM, Matchett WE, et al. Measles virus defective interfering RNAs are generated frequently and early in the absence of C protein and can be destabilized by adenosine deaminase acting on RNA-1-Like hypermutations. J Virol. 2015;89(15):7735&#x2013;7747.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4505647</ArticleId><ArticleId IdType="pubmed">25972541</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergh&#xe4;ll H, Sir&#xe9;n J, Sarkar D, et al. The interferon-inducible RNA helicase, mda-5, is involved in measles virus-induced expression of antiviral cytokines. Microbes Infect. 2006;8(8):2138&#x2013;2144.</Citation><ArticleIdList><ArticleId IdType="pubmed">16782388</ArticleId></ArticleIdList></Reference><Reference><Citation>Cattaneo R, Schmid A, Eschle D, et al. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell. 1988;55(2):255&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7126660</ArticleId><ArticleId IdType="pubmed">3167982</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomeli H, Mosbacher J, Melcher T, et al. Control of kinetic properties of AMPA receptor channels by nuclear RNA editing. Science. 1994;266(5191):1709&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pubmed">7992055</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoft VK, Schopoff S, Jantsch MF. Regulation of glutamate receptor B pre-mRNA splicing by RNA editing. Nucleic Acids Res. 2007;35(11):3723&#x2013;3732.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1920255</ArticleId><ArticleId IdType="pubmed">17517775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ven&#xf8; M, Bramsen JB, Bendixen C, et al. Spatio-temporal regulation of ADAR editing during development in porcine neural tissues. RNA Biol. 2012;9(8):1054&#x2013;1065.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3551860</ArticleId><ArticleId IdType="pubmed">22858680</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachernegg S, M&#xfc;nster Y, Muth-K&#xf6;hne E, et al. GluA2 is rapidly edited at the Q/R site during neural differentiation in vitro. Front Cell Neurosci. 2015;9:69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4350408</ArticleId><ArticleId IdType="pubmed">25798088</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbon A, Barlati S. Glutamate receptor RNA editing in health and disease. Biochemistry (Mosc). 2011;76(8):882&#x2013;889.</Citation><ArticleIdList><ArticleId IdType="pubmed">22022961</ArticleId></ArticleIdList></Reference><Reference><Citation>Egebjerg J, Heinemann SF. Ca2+ permeability of unedited and edited versions of the kainate selective glutamate receptor GluR6. Proc Natl Acad Sci U S A. 1993;90(2):755&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC45744</ArticleId><ArticleId IdType="pubmed">7678465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohler M, Burnashev N, Sakmann B, et al. Determinants of Ca2+ permeability in both TM1 and TM2 of high affinity kainate receptor channels: diversity by RNA editing. Neuron. 1993;10(3):491&#x2013;500.</Citation><ArticleIdList><ArticleId IdType="pubmed">7681676</ArticleId></ArticleIdList></Reference><Reference><Citation>Paschen W, Schmitt J, Gissel C, et al. Developmental changes of RNA editing of glutamate receptor subunits GluR5 and GluR6: in vivo versus in vitro. Brain Res Dev Brain Res. 1997;98(2):271&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">9051270</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard A, Ferhat L, Dessi F, et al. Q/R editing of the rat GluR5 and GluR6 kainate receptors in vivo and in vitro: evidence for independent developmental, pathological and cellular regulation. Eur J Neurosci. 1999;11(2):604&#x2013;616.</Citation><ArticleIdList><ArticleId IdType="pubmed">10051761</ArticleId></ArticleIdList></Reference><Reference><Citation>Vissel B, Royle GA, Christie BR, et al. The role of RNA editing of kainate receptors in synaptic plasticity and seizures. Neuron. 2001;29(1):217&#x2013;227.</Citation><ArticleIdList><ArticleId IdType="pubmed">11182093</ArticleId></ArticleIdList></Reference><Reference><Citation>Sailer A, Swanson GT, P&#xe9;rez-Ota&#xf1;o I, et al. Generation and analysis of GluR5(Q636R) kainate receptor mutant mice. J Neurosci. 1999;19(20):8757&#x2013;8764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782774</ArticleId><ArticleId IdType="pubmed">10516295</ArticleId></ArticleIdList></Reference><Reference><Citation>Burnashev N, Zhou Z, Neher E, et al. Fractional calcium currents through recombinant GluR channels of the NMDA, AMPA and kainate receptor subtypes. J Physiol. 1995;485(Pt 2):403&#x2013;418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1158001</ArticleId><ArticleId IdType="pubmed">7666365</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortinski PI, Lu C, Takagaki K, et al. Expression of distinct &#x3b1; subunits of GABAA receptor regulates inhibitory synaptic strength. J Neurophysiol. 2004;92(3):1718&#x2013;1727.</Citation><ArticleIdList><ArticleId IdType="pubmed">15102896</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohlson J, Pedersen JS, Haussler D, et al. Editing modifies the GABA(A) receptor subunit alpha3. Rna. 2007;13(5):698&#x2013;703.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852825</ArticleId><ArticleId IdType="pubmed">17369310</ArticleId></ArticleIdList></Reference><Reference><Citation>Buckanovich RJ, Yang YY, Darnell RB. The onconeural antigen Nova-1 is a neuron-specific RNA-binding protein, the activity of which is inhibited by paraneoplastic antibodies. J Neurosci. 1996;16(3):1114&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6578795</ArticleId><ArticleId IdType="pubmed">8558240</ArticleId></ArticleIdList></Reference><Reference><Citation>Irimia M, Denuc A, Ferran JL, et al. Evolutionarily conserved A-to-I editing increases protein stability of the alternative splicing factor Nova1. RNA Biol. 2012;9(1):12&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">22258141</ArticleId></ArticleIdList></Reference><Reference><Citation>Striessnig J, Koschak A. Exploring the function and pharmacotherapeutic potential of voltage-gated Ca2+ channels with gene knockout models. Channels (Austin). 2008;2(4):233&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">18719397</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Tan B, Shen Y, et al. RNA editing of the IQ domain in Cav1.3 channels modulates their Ca2+-dependent inactivation. Neuron. 2012;73(2):304&#x2013;316.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3271027</ArticleId><ArticleId IdType="pubmed">22284185</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JB, Levanon EY, Yoon JK, et al. Genome-wide identification of human RNA editing sites by parallel DNA capturing and sequencing. Science. 2009;324(5931):1210&#x2013;1213</Citation><ArticleIdList><ArticleId IdType="pubmed">19478186</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake K, Ohta T, Nakayama H, et al. CAPS1 RNA editing promotes dense core vesicle exocytosis. Cell Rep. 2016;17(8):2004&#x2013;2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5199237</ArticleId><ArticleId IdType="pubmed">27851964</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulbricht R, Sun S, DelBove C, et al. RNA editing of CAPS1 regulates synaptic vesicle organization, release and retrieval. bioRxiv. 2017;178202</Citation></Reference><Reference><Citation>Terajima H, Yoshitane H, Ozaki H, et al. ADARB1 catalyzes circadian A-to-I editing and regulates RNA rhythm. Nat Genet. 2017;49(1):146&#x2013;151.</Citation><ArticleIdList><ArticleId IdType="pubmed">27893733</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">14744438</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang W, Chendrimada TP, Wang Q, et al. Modulation of microRNA processing and expression through RNA editing by ADAR deaminases. Nat Struct Mol Biol. 2006;13(1):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2950615</ArticleId><ArticleId IdType="pubmed">16369484</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Megraw M, Kreider E, et al. Frequency and fate of microRNA editing in human brain. Nucleic Acids Res. 2008;36(16):5270&#x2013;5280.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2532740</ArticleId><ArticleId IdType="pubmed">18684997</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Zinshteyn B, Chendrimada TP, et al. RNA editing of the microRNA-151 precursor blocks cleavage by the Dicer-TRBP complex. EMBO Rep. 2007;8(8):763&#x2013;769</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1978079</ArticleId><ArticleId IdType="pubmed">17599088</ArticleId></ArticleIdList></Reference><Reference><Citation>Iizasa H, Wulff B-E, Alla NR, et al. Editing of epstein-barr virus-encoded BART6 microRNAs controls their dicer targeting and consequently affects viral latency. J Biol Chem. 2010;285(43):33358&#x2013;33370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2963350</ArticleId><ArticleId IdType="pubmed">20716523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekdahl Y, Farahani HS, Behm M, et al. A-to-I editing of microRNAs in the mammalian brain increases during development. Genome Res. 2012;22(8):1477&#x2013;1487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409261</ArticleId><ArticleId IdType="pubmed">22645261</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul D, Sinha AN, Ray A, et al. A-to-I editing in human miRNAs is enriched in seed sequence, influenced by sequence contexts and significantly hypoedited in glioblastoma multiforme. Sci Rep. 2017;7(1):2466.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5446428</ArticleId><ArticleId IdType="pubmed">28550310</ArticleId></ArticleIdList></Reference><Reference><Citation>Vesely C, Tauber S, Sedlazeck FJ, et al. ADAR2 induces reproducible changes in sequence and abundance of mature microRNAs in the mouse brain. Nucleic Acids Res. 2014;42(19):12155&#x2013;12168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4231736</ArticleId><ArticleId IdType="pubmed">25260591</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Zinshteyn B, Sethupathy P, et al. Redirection of silencing targets by adenosine-to-inosine editing of miRNAs. Science. 2007;315(5815):1137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2953418</ArticleId><ArticleId IdType="pubmed">17322061</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore R, Khudayberdiev S, Christensen M, et al. Mef2-mediated transcription of the miR379&#x2013;410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. Embo J. 2009;28(6):697&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2647767</ArticleId><ArticleId IdType="pubmed">19197241</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaselli S, Galeano F, Alon S, et al. Modulation of microRNA editing, expression and processing by ADAR2 deaminase in glioblastoma. Genome Biol. 2015;16(1):5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326501</ArticleId><ArticleId IdType="pubmed">25582055</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury Y, Tay FC, Lam DH, et al. Attenuated adenosine-to-inosine editing of microRNA-376a* promotes invasiveness of glioblastoma cells. J Clin Invest. 2012;122(11):4059&#x2013;4076.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3484441</ArticleId><ArticleId IdType="pubmed">23093778</ArticleId></ArticleIdList></Reference><Reference><Citation>Quinones-Valdez G, Tran SS, Jun H-I, et al. Regulation of RNA editing by RNA-binding proteins in human cells. Commun Biol. 2019;2(1):19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6331435</ArticleId><ArticleId IdType="pubmed">30652130</ArticleId></ArticleIdList></Reference><Reference><Citation>Hwang T, Park CK, Leung AK, et al. Dynamic regulation of RNA editing in human brain development and disease. Nat Neurosci. 2016;19(8):1093&#x2013;1099</Citation><ArticleIdList><ArticleId IdType="pubmed">27348216</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalk AM, Taylor S, Heraud-Farlow JE, et al. The majority of A-to-I RNA editing is not required for mammalian homeostasis. Genome Biol. 2019;20(1):268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6900863</ArticleId><ArticleId IdType="pubmed">31815657</ArticleId></ArticleIdList></Reference><Reference><Citation>Montiel-Gonzalez MF, Diaz Quiroz JF, Rosenthal JJC. Current strategies for site-directed RNA editing using ADARs. Methods. 2019;156:16&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6814296</ArticleId><ArticleId IdType="pubmed">30502398</ArticleId></ArticleIdList></Reference><Reference><Citation>Picardi E, Horner DS, Pesole G. Single-cell transcriptomics reveals specific RNA editing signatures in the human brain. Rna. 2017;23(6):860&#x2013;865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435858</ArticleId><ArticleId IdType="pubmed">28258159</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>